Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-788

First 788 Last

Share
Profile

Follow
redbaron

2,122 Posts.

92

27/04/20

11:26

Post #: 44275476
Share

Originally posted by bedger: ↑

Lets get this thread and others with more informative postings back to the top of the debate, rather than silly 'its going to collapse' or 'its going to rally' threads.

$4.60+ after hours US equivalent trading clearly disrupted by CNN piece over the weekend. For those who didn't see the cohort study group of 90% ventilator deaths in NY called into question. Like so many stats around the world of late, poorly presented. UK did similar in their ventilator study. Called death rates before outcomes known.

HK Uni study of complete Chinese data (that they had control over) showed 80% COVID-19 related death rates on ventilators. Excellent studies that literally predicted global outbreak back in Jan 31 (I missed).

Even if you look at NON COVID-19 deaths, ARDS patients on ventilators show 33-50% death rates.

MSB made a mistake referring to 90% mortality rates and should have stayed focused on 9% recovery rates in cohort study. It does not detract from MSB's brilliant results. The tragedy will be if MSB's clear resolution of cytokine storms (the thing that literally kills everyone in COVID-19 related deaths) gets over-looked because of this.

I am on GILEAD, the next best candidate. Whilst Remdesivir addresses replication, it also takes a toll on kidneys. Guess what the second largest problem in COVID-19 deaths is after ARDS? Yes, Kidney failure. Guess what is shown in such COVID-19 failures? Cytokine storms dramatically reduce blood flow to the kidney, causing often-fatal damage.

This pause on the MSB rally is a buy-in opportunity longer term. This drug addresses exactly the biological reaction of our bodies (cytokine storms) that causes organ failure in COVID-19 associated deaths, by the body's very own natural mechanisms. No blockers. No suppressants. Just the body's own natural immune response processes encouraged by stem cells.

I will hold through the full reports of the ventilator/ARDS studies, then through inevitable non-ARDS trials when people round the world suddenly realise through all the noise of (unlikely) vaccines (long explanation, but basically they never were able to create a vaccine for SARS from 2002 is my quickest illustration) that MSB's Remestemcel-L treatment is the gold star treatment for COVID-19 related deaths.

Expand

Have you considered any other ARDS treatment modalities like Interleukin-6. They are running clinical trials as well!
Good to compare orange with orange!
GLAH

MSB Price at posting: $3.91 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Making money: How many microcaps should be in an investor's portfolio?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Finance school vs reality: What they don't teach you about the stock market

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

There are more pages in this discussion • 60 more messages in this thread...

First 788 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.31		Change 0.040(3.16%)		Mkt cap ! $1.490B

Open	High	Low	Value	Volume
$1.28	$1.32	$1.26	$3.433M	2.652M

Buyers (Bids)

No.	Vol.	Price($)
2	39558	$1.30

Sellers (Offers)

Price($)	Vol.	No.
$1.31	21776	3

View Market Depth

No.	Vol.	Price($)
2	39558	1.300
3	26433	1.295
6	108207	1.290
2	47468	1.285
3	10889	1.280

Price($)	Vol.	No.
1.310	21776	3
1.315	57441	5
1.320	2500	1
1.325	61160	4
1.330	15000	2

Last trade - 16.10pm 28/10/2024 (20 minute delay)

MSB (ASX) Chart

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-788

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Making money: How many microcaps should be in an investor's portfolio?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Finance school vs reality: What they don't teach you about the stock market

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-788

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Making money: How many microcaps should be in an investor's portfolio?

'We're looking': Nickel-rich Indonesia sounds graphite warning to Aus producers

Finance school vs reality: What they don't teach you about the stock market

The Altcoin Landscape (Part 1): Key alternative cryptocurrencies to watch

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News